Expansion opportunity Invest in Jubilant Radiopharma’s planned $50 million expansion of PET radiopharmaceutical manufacturing capacity to scale supply for diagnostic and therapeutic radiopharmaceuticals, offering collaboration on capacity planning, outsourced manufacturing, or co-development of new tracers.

Product portfolio Target their broad diagnostic and therapeutic radiopharmaceutical portfolio across cardiology, oncology, pulmonology, and endocrinology with high-value kits, tracers, and related devices, emphasizing joint development and ready-to-use solutions for hospitals and clinics.

Strategic partnerships Leverage ongoing and past partnerships (Evergreen Theragnostics, Isotopia, CNL) to propose complementary distribution, regional sales expansion, and integrated supply agreements to strengthen US and Canadian market presence.

Digital adoption Align with their tech stack including SAP S/4HANA and Planful to offer end-to-end commercial solutions such as digital contract management, forecasting, and analytics for radiopharmaceutical demand, quality tracking, and revenue optimization.

Growth signals Capitalize on recent leadership transitions in global sales and a revenue base in the multi‑tens of millions by positioning value-added services, training programs, and volume-based pricing to expand hospital, academic, and government customer segments.